Sherlock Biosciences posts $34.9M net loss, $149.7M deficit in 9 months before OraSure acquisition

ORASURE TECHNOLOGIES INC

Net loss of $34.9M for nine months ended Sep 30, 2024; $50.9M loss for FY2023.
Accumulated deficit reached $149.7M as of Sep 30, 2024; total liabilities $55.3M exceed assets $31.1M.
Cash and cash equivalents $3.8M at Sep 30, 2024; convertible notes of $27.9M outstanding.
Revenue from grants only $1.1M in 9 months 2024, $0.9M in FY2023; no product revenue.
Going concern uncertainty noted, but expected to be resolved by OraSure acquisition in Dec 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.